Our primary focus is on the development of novel therapeutics and platforms. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program.
Invest Globally:
We invest in North America, Europe and Israel with approximately USD 750 million under management in committed capital. We continue our strategy of making larger focused investments and anticipate total investments up to USD 30 million per company over its life.
Invest Across Healthcare Sector:
We make equity investments in Biotechnology/Biopharma life sciences companies. NVF is stage agnostic and engages in seed investments as well as later-stage investments. We typically lead or co-lead an investment and play an active role on company boards.